News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
no_dataFlash
09:52
In a clinical trial conducted in Copenhagen, Novo Nordisk's weight-loss drug failed to outperform Eli Lilly's competing product.Boosted by this news, Eli Lilly's stock price rose by 2.1% in pre-market trading. This result has further intensified the fierce competition between the world's two pharmaceutical giants in the highly lucrative weight-loss drug market.
09:49
SOL surpasses $80Jinse Finance reported that according to market data, SOL has surpassed $80 and is now trading at $80.06, with a 24-hour decline of 5.96%. The market is experiencing significant volatility, so please ensure proper risk management.
09:49
US Stocks Move: Eli Lilly Rises Over 2% in Pre-market TradingGelonghui, February 23rd｜Eli Lilly's US stock rose 2.6% in pre-market trading. According to reports, Novo Nordisk's weight-loss drug performed less effectively than Eli Lilly's in the CagriSema trial.
News